EUCOPE, in partnership with Sanofi, participated in the European Health Forum Gastein 2021 (EHFG) on 29 September in a session on rare diseases to discuss what is needed to stimulate basic research, clinical development, and access to care across the EU in light of the… read more
The European Commission is consulting stakeholders as part of its revision process of two major pieces of legislation, on medicines for rare diseases and paediatric patients. Central to the development of innovative treatments for these specific categories of patients, this revision process represents an important… read more
As proven by the fight against COVID-19, data and digital health have the potential to drive change and improve efficiency and accessibility in healthcare. To make the most of this enormous potential, the European Commission opened a public consultation on the European Health Data Space,… read more
The complexities related to delivering some Advanced Therapy Medicinal Products (ATMPs) most likely will require highly specialized clinical expertise and infrastructures, which currently do not exist in all EU counties. Therefore, relocating or crossing borders often represent the only solution for many patients. A well-developed… read more
The multidisciplinary European Expert Group on Orphan Drug Incentives (OD Expert Group) has developed fourteen innovative proposals along the entire lifecycle of orphan drug development to address the unmet needs in rare diseases. With over ninety percent of patients without a centrally approved treatment option,… read more
The COVID-19 pandemic has again made the vital importance of the European pharmaceutical sector apparent, and while regulatory simplification is welcomed, broader business incentives should also be considered to address the EU’s competitiveness. In its response to the EU roadmap/IIA on the “Evaluation and revision of… read more
The objective of EUCOPE’s Advanced Diagnostics Working Group The Advanced Diagnostics Working Group is made up of diagnostics companies that have come together to ensure Europe will be able to draw benefit from the significant advances that have been made in genomic testing. The group… read more
On 7 May, the European Commission opened its public consultation on the revision of EU rules on medicines for children and rare diseases. The consultation, aimed at stakeholders and members of the general public, including patients and doctors, will explore several options to address the shortcomings… read more
Today marks the release of the first episode of Sounds of Science, a series of podcasts organized by EUCOPE, discussing pressing EU files and presenting the point of view of EUCOPE and its members in an informative and interactive way. In this first podcast, Ana… read more
Working group of European rare disease experts developed nine principles to foster greater consistency in Value Assessment and Funding Process in rare diseases. The group explored the pricing and reimbursement systems for OMPs in selected European countries to analyse where they align with or diverge from… read more
Keep up-to-date on all of the most pertinent policy files and regulatory news around the world of European health technologies with our monthly newsletter – the Innovation Eye-View
You are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
You are currently viewing a placeholder content from Instagram. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
You are currently viewing a placeholder content from X. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.